In a study published in Nature on Oct. 11, coinciding with the beginning of IDWeek 2023 in Boston, researchers from Harvard Medical School described EVEscape, a method for anticipating the movements of SARS‑CoV‑2 by predicting potential mutations likely to escape current vaccines and treatments.
Due to the continual emergence of SARS-CoV-2 mutants, there is an unmet clinical need for broad-spectrum treatments for COVID-19. A potential target for novel treatments is the S2 subunit of the SARS-CoV-2 spike (S) protein, which has been highly conserved across the different variants of the virus.
In a study published in Nature on Oct. 11, coinciding with the beginning of IDWeek 2023 in Boston, researchers from Harvard Medical School described EVEscape, a method for anticipating the movements of SARS‑CoV‑2 by predicting potential mutations likely to escape current vaccines and treatments.
Recently, researchers at Cincinnati Children’s Hospital, in collaboration with colleagues in Japan, have developed a human vascular organoid model that accurately mimics the vascular damage caused by SARS-CoV-2.
Aerium Therapeutics Inc. has licensed and commenced development of three monoclonal antibodies (MAbs) with broad and potent activity against the predominant variants of SARS-CoV-2, including those containing the F456L mutation, such as EG.5.1. These antibodies could provide an option to protect immunocompromised populations from severe COVID-19.
The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ (HHS) Administration for Strategic Preparedness and Response, has awarded Vir Biotechnology Inc. approximately $50 million in new funding to advance the development of novel monoclonal antibody (MAb) candidates and delivery solutions to widen the applicability of MAbs in COVID-19 and in pandemic preparedness and response.
Complementarity-determining regions (CDRs) are relatively short peptide loops in antibodies where they bind to their specific antigens. Bovines, unlike humans and other vertebrates, rely on ultralong CDR H3 antibody knob regions to neutralize cryptic viral epitopes.
Modex Therapeutics Inc. has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) to advance a platform and specific candidates designed to address a range of public health threats in viral infectious diseases.
Viruses of the Betacoronavirus genus that bind to angiotensin-converting enzyme 2 (ACE2) are the coronaviruses posing the most significant pandemic risk. Sarbecoviruses of this genus caused the severe acute respiratory syndrome (SARS) epidemic and the SARS-CoV-2 pandemic. Therefore, new vaccines with broader protection from ACE2-binding sarbecoviruses and emerging variants of concern are urgently needed.
